Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients

Major depressive disorder (MDD) is one of the most common psychiatric disorders with serious socioeconomic consequences on daily life and health care costs. Despite the advent of newer antidepressants that target monoamine pathways, nearly 50% of patients have no response to first-line antidepressant therapy. Thus, a combination of medications with different strategies at the beginning of treatment could provide further therapeutic benefits to MDD patients

NCT Number	NCT06860958
Lead Sponsor	Tanta University
Conditions	Depressive Disorder, Major
Enrollment	60 participants
Start Date	2025-03-01
Primary Completion	2027-03-20 (estimated)
Study Completion	2027-08-20 (estimated)
Updated on ClinicalTrials.gov	2026-05-04